dr. pal on the checkmate-214 and cabosun studies in rcc
Published 6 years ago • 143 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
0:51
dr. pal on the safety profile of cabozantinib/atezolizumab in advanced rcc
-
31:14
current treatment of advanced renal cell carcinoma, christian kollmannsberger, md
-
1:23:33
fine-tuning the wave of innovation in rcc
-
18:04
panel shares thoughts on rcc data: checkmate 914, 214 and imdc selection criteria
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
1:21
dr. powles on the 42-month follow-up data from the checkmate-214 trial in rcc
-
0:50
dr. pal on the benefit of tivozanib in later-line settings for refractory rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
0:41
dr. pal on molecular signatures in renal cell carcinoma
-
0:43
dr. pal on sequencing nivolumab in rcc
-
1:37
dr. amin on rationale for checkmate-214 trial in rcc
-
1:06
dr. agarwal on the checkmate-214 trial for kidney cancer
-
1:01
dr. pal on sequencing challenges for the treatment of patients with rcc
-
0:48
dr. pal on preoperative immunotherapy in patients with rcc
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
1:54
checkmate 214 trial in rcc updates
-
1:14
dr. choueiri on significance of checkmate-025 study for rcc